Dementia treatment with targeted therapy (Aduhelm)

Currently, a complete cure for dementia isn’t possible. Still, medical practitioners are working on developing new methods for disease management. Lately, a significant impact of beta-amyloid on dementia’s progression was discovered. Accumulating excessive amounts of beta-amyloid in the patient’s nervous system is strongly related to dementia symptoms. As a result, healthcare practitioners developed a medication that helps eliminate excessive beta-amyloid and slow down dementia progression. It is a monoclonal antibody called Aduhelm. It’s essential to notice that Aduhelm will not entirely stop the production of beta-amyloid but can significantly decrease the intensity of this process. So, the earlier the treatment begins, the better results the patient will get. Aduhelm will help save memory, learning, behavior, and thinking for much longer in patients with Parkinson, Alzheimer, and senile dementia, but it almost certainly doesn’t help renew lost functions. During the treatment, patients will also get all the necessary therapy for various other dementia-related symptoms like depression, anxiety, aggression, agitation, and many others. The number and dosage of medication might vary depending on the condition, present symptoms, and other clinically-related factors.